AMD Alliance International organizes video contest to raise awareness
October 2nd 2009AMD Alliance International is hosting a video contest to raise awareness for age-related macular degeneration (AMD). Individuals are invited to create and submit videos of no longer than 3 minutes that will communicate in the most creative and visually interesting ways the impact of AMD.
Prognosis for recovery vital to facial nerve palsy management
October 1st 2009Protection of the eye is the most important issue to address in patients with facial nerve paralysis because corneal damage can result from increased surface exposure and disruption of the tear film. Management of facial nerve palsy depends on an individual's prognosis for recovery. Most patients will have spontaneous, complete recovery.
Immune agents target inflammation
October 1st 2009Corticosteroids remain the primary treatment for inflammatory diseases that involve the eye and orbit. However, side effects and treatment failures have provided the impetus for the use of safer and more specific immunosuppressive agents. The selection of a specific agent will depend on multiple factors. The next step in the use and development of alternative immune agents will likely involve both the identification of inflammatory conditions that are most responsive to a particular agent and identifying patient-specific factors that might predict a response to that agent.
FDA approves bepotastine for ocular itching
October 1st 2009The recent FDA approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis gives clinicians an additional treatment option, one with multiple mechanisms of action and a rapid onset of action.